Background: The association of morphine and baclofen is used for the treatment of spasticity related pain. Moving these patients is sometimes difficult. In order to transport these syringes for pump refilling, it could be interesting to demonstrate the stability of the mixture, and so to be able to ensure the best transport conditions of syringes. Methods: A stability indicating UPLC-DAD method was developed and validated according to the ICH guidelines. Two mixtures of morphine and baclofen -a low concentration mixture (morphine 1 mg/mL -baclofen 0.08 mg/mL) and a high concentration mixture (morphine 10 mg/mLbaclofen 1.6 mg/mL) stored in 5 ± 3°C and 25 ± 2°C were evaluated for seven days and compared to the initial observed concentrations. Results: The stability of the low and high mixture is demonstrated for both storage conditions for seven days thanks to relative concentrations (95 % confidence intervals of the mean of 3 samples) systematically positioned between 95 % and 105 %. No degradation product was observed during the stability study. Conclusion: This study shows the stability of a weakly concentrated mixture and a highly concentrated mixture of morphine and baclofen. Extrapolation of these data to an intermediate mixture may be considered. Further studies will support this hypothesis. This result will allow the transport of the preparation under optimal
Introduction
Spinal spasticity and pain are often associated with certain pathologies such as multiple sclerosis, spinal cord injury or transverse myelitis. Baclofen is frequently used against spinal spasticity (1, 2) and its use with an intrathecal pump is FDA approved (3) . It is an agonist of the gamma aminobutyric acid (GABA)-B receptors which implies an increase of potassium conductance, through a G-protein mechanism with a second messenger system, producing thus membrane hyperpolarization (4) .
Studies have focused on the use of baclofen for nociceptive pain (5, 6) . Its use in other chronic pain not related to spasticity is poorly documented. However, a study of 5 patients showed an average reduction of 76 % in pain caused by arachnoiditis/epidural scarring, lumbar plexopathy, phantom pain, and sciatic neuropathy (7) .
Other studies report that combined intrathecal baclofen-morphine therapy is safe and effective in spasticity related pain (8, 9) . Morphine is an agonist of opiate receptors (mu, kappa and delta) which are found, among other locations, in the spinal cord dorsal horn. That molecule provides a strong analgesia by decreasing the ascending pain transmission system, as well as reinforcing the descending inhibitory system (10) .
Few centers in France use the method of intrathecal analgesia. The method requires proper staff and equipment. Those preparations are in general realized in hospital pharmacy, in sterile conditions under a laminar air flow hood and released after a successful analytical control. The drugs are generally mixed together alone or with normal saline solution in polypropylene syringes (11) .
Therefore, to limit patient movements, it could be interesting to send those preparations to peripheral establishment located near patient's home which could manage the implantable pump refill. In practice, concentrations of morphine and baclofen vary from one preparation to another.
To our knowing, there is no stability study of the morphine baclofen association in 0.9 % sodium chloride solution in polypropylene syringes. It could be interesting to demonstrate the stability of the mixture, and so to be able to ensure the best transport conditions of syringes.
Thus, the aim of this study was to report the stability of the morphine baclofen association, at two different concentrations (morphine 1 mg/mL -baclofen 0.080 mg/mL; morphine 10 mg/mL -baclofen 1.6 mg/mL), in polypropylene syringes stored at 5 ± 3°C and 25 ± 2°C.
Material and methods

Medications and reagents
Mixtures were prepared using sterile commercially available solutions. Morphine vials were bought from CDM Lavoisier (La Chaussée Saint Victor, France). It's an intravenous and intrathecal formulation of 50 mg/mL morphine sulfate including the excipients water for injection, hydrochloric acid and sodium chloride. Baclofen (Lioresal ® ) vials were bought from Novartis Pharma (Rueil-Malmaison, France). It is available under a formulation of 2 mg/mL for intrathecal infusion, including the excipients sodium chloride and water for injection. All reagents and chemicals are analytical grade included acetonitrile for HPLC (VWR, Fontenay aux Roses, France) and trifluoroacetic acid (Sigma-Aldrich, Saint-Louis, USA). Ultrapure water was obtained from Elga Purelab DV25 system. Oxygen peroxide (H 2 O 2 ) 3 % w/v was bought from Gifrer (Decines, France) and 0.9 % sodium chloride solution (NaCl) from Fresenius Kabi (Sèvre, France).
Preparations
Briefly, morphine and baclofen solutions were mixed together and diluted with 0.9 % sodium chloride solution in a 50 mL polypropylene syringe (BD, Le Pont de Claix, France). The obtained concentrations are listed in Table 1 . Three preparations were realized for each mixture studied at each storage condition. All syringes were protected from light and packaged in a sterile sachet.
Storage conditions and sampling schedule
Two storage conditions were tested for syringes: 5°C ± 3°C and 25°C ± 2°C. The temperature of the storage area was monitored to ensure its consistency. Concentrations measured immediately after preparations were considered as the reference (D0). Then, syringes were taken out for analysis after one day, two days, three days, five and seven days. Samples collected were introduced in a 2 mL glass vials (Interchim, Monluçon, France) for chromatographic analysis.
Quantification method Equipment and chromatographic conditions
Morphine and baclofen concentrations of each sample were measured using Ultra Performance Liquid Chromatography (Acquity UPLC H-Class ® , Waters, Guyancourt, France). The system is interfaced to a Photodiode Array Detector (PDA) operating between 190-400 nm and managed by the Empower™ software (Waters, Guyancourt, France). After a 0.3 µL injection, samples were analyzed on a C-18 reversed phase column heated at 50°C (Acquity UPLC ® BEH, 2.1 x 50 mm, 1.7 µm). The mobile phase was a gradient of ultrapure water with 0.1 % trifluoroacetic acid (aequous phase) and acetonitrile with 0.1 % trifluoroacetic acid (organic phase). The flow rate was set to 0.5 mL/min and the run time was fixed to 6.5 min. Quantification of morphine and baclofen were carried out respectively at 280 and 220 nm.
Method parameters
The method was developed and validated according to the International Conference of Harmonization (ICH Q2 R1) (12) . The linearity of the method was assessed by three standard curves of six points, realized on three different days by three different manipulators. The ranges were respectively from 0.15 to 25.0 mg/mL and 0.0625 to 2.0 mg/mL for morphine and baclofen. A linear relationship was validated for the method if the mean correlation coefficient (r 2 ) was over 0.999 for the morphine and also for the baclofen. The accuracy was evaluated by measured three quality controls (QC) (1, 10 and 22.5 mg/mL for morphine, 0.1, 0.9 and 1.9 mg/mL for baclofen) three times a day, for three days. For each concentration, the difference between the mean of the QC and the true value has to be less than 5 % to have an acceptable accuracy. The repeatability was assessed by assaying six times a solution of 22.5 mg/mL of morphine as well as a solution of baclofen at 0.9 mg/mL. These assays were repeated over three days. Repeatability was determined by using the intra-day Relative Standard Deviation (RSD) and intermediate precision by using the inter-day RSD. Again, values had to be less than 5 % to be validated. To demonstrate the specificity of the method three samples containing the other active substances in a mean concentration and the excipient (NaCl 0.9 %) has been checked. The specificity of the method was validated if the assay results were unaffected by the presence of impurities, the other substance or excipients. To demonstrate the stability indicating capability of the method, a forced degradation study was carried out. This was validated if the assay results highlight degradation products.
Stability indicating method
As far as it was possible, a degradation of around 10 % of the active substances was carried out. Forced degradation was conducted by exposing 1 mg/mL samples to basic and acid hydrolysis, oxidation, photo degradation and thermal stress. The basic and acid degradation were performed by adding a NaOH or HCl solution. Those samples were neutralized before analysis. Oxidation was conducted by adding a 3 % w/w H 2 O 2 solution. The photo degradation was performed by exposing samples to an UV-lamp (312 nm). Finally, the thermal stress was carried out by storing samples in an oven at 37°C. The various stress conditions used are more detailed in Table 2 . If present, degradation products were identified by their relative retention to the main substance. In addition, the mass balance was determined.
Determination of morphine and baclofen concentrations
Samples were analyzed in triplicate. The relative concentrations of drugs were expressed as a percentage of the initial concentrations measured on day 0, which were considered as the reference. Moreover, each mean percentage was calculated as well as their 95 % confidence interval (CI 95 %). The acceptance criterion for the chemical stability was that every CI 95 % lower bounds had to be above 95 % of the reference (i. e. the mean value at day 0).
pH determinations
The variation of pH was determined in triplicate for each sampling time with a glass micro-electrode connected to a pH meter (Hanna Instrument, Tanneries, France).
Physical stability
Visual observations of possible physical alterations, such as color changes, appearance of precipitated or muddy samples, have been carried out. It was performed by direct sample observation on a black and white background. Moreover, turbidity assays were conducted in triplicate for each sampling time. The measurements were carried out at 350 and 700 nm with a Nanodrop ® ND-1000 spectrophotometer (Thermo scientific, Waltham, USA). 
Results
Method parameters
For morphine and baclofen, retention times were found respectively as 0.544 and 1.676 min. No interfering peaks were detected at the specific retention times. The absence of interference by the other active substances of the mixture, impurities or excipients has been validated for the two analytes. Peaks were symmetric and well defined (Figure 1 ). Concerning the linearity, the mean correlation coefficient of the three morphine standard curves was greater than 0.999. Likewise, for the baclofen, the mean correlation coefficient was superior to 0.999. About the accuracy, results were 1.55 %, 0.03 % and 0.85 % respectively for the 1, 10 and 22.5 mg/mL morphine QC. For the baclofen, results were 2.2 %, 2.1 % and 3.2 % respectively for the 0.1, 0.9 and 1.9 mg/mL QC. Concerning the repeatability, the intra-day RSD of the 22.5 mg/mL morphine solution were 0.1 %, 0.2 % and 0.1 % respectively on day 1, 2 and 3. About baclofen, intra-day RSD were 0.2 %, 1.7 % and 0.1 %. Next, inter-day RSD was 0.84 % for morphine and 1.1 % for baclofen.
Stability indicating method Morphine
Under photolytic stress, a decrease of 10 % of morphine sulfate was shown comparing to her standard chromatogram. Moreover, two additional peaks were also observed ( Figure 2 ) and the mass balance reached 99.7 %. Concerning these morphine degradation products, retention times were found respectively as 0.338 and 1.923 min. A yellow coloration of this sample exposed to light was observed. No decrease was highlighted with basic and acid hydrolysis, oxidation, and thermal stress tested.
Baclofen
Under oxidative stress, a decrease of 13 % of baclofen was shown comparing to his standard chromatogram. Two additional peaks were also observed ( Figure 2 ). The mass balance displayed 99.3 %. For baclofen degradation products, retention times were found respectively as 1.201 and 1.546 min. No decrease was spotted with basic and acid hydrolysis, photo degradation, and thermal stress tested. Finally, no interference between the two molecules and the degradation products was observed.
Stability study and relative concentrations
Relative concentrations measured during the stability study are presented in Table 3 . After seven days and whatever the study conditions, every 95 % confidence intervals calculated had their lower bounds greater than 95 %. In addition, no degradation product has been observed over the time.
pH determinations
No pH modification was observed during the whole stability study. About mixture 1, mean pH values at day 0 and day 7 were 6.9 and 7.0 respectively for 5°C ± 3°C and 25°C ± 2°C. For mixture 2, mean pH value was 5.7 at day 0 and day 7, for both 5°C ± 3°C and 25°C ± 2°C.
Physical stability
No modification of samples visual aspect was observed during the stability study. Likewise, no change was observed concerning turbidity assays. Whatever the mixture, storage conditions and day of assay, mean values of absorbance remained inferior to 0.007.
Discussion Method parameters
Correlation coefficients of morphine and baclofen mean standard curves were greater than 0.999. Thus, the linear relationship has been validated. In addition, the method has been validated as accurate, repeatable and with correct intermediate precision thanks to parameters evaluated under the 5 % threshold set before to begin.
Stability indicating method
The developed method effectively separated morphine sulfate from degraded products. Two of them were observed. These results are in accordance with the wellknown degradation pathway of morphine in solution: Table 3 : Morphine and Baclofen concentrations along time after storage, expressed as the 95 % confidence interval of the mean.
Nominal Concentration
Time of Analysis
pseudomorphine as the principal degradation product and morphine N-oxyde as the minor one (13) . The yellow coloration observed after photo degradation is also known. However, our analytical method based on UV detection is not able to fully characterize those degradation products. The method also showed a good separation between baclofen and degraded products. Finally, results of mass balance superior to 99 % for both morphine and baclofen implied that the method is stabilityindicating for these two molecules and that all degradation products could be observed during the stability study.
Stability study and relative concentrations
Relative concentrations of morphine and baclofen stayed very close to the reference (day 0), in the two concentrations studied (mixture 1 and 2) as well as for the two storage conditions. No degradation product was observed over the study. It can be explained by two facts. First, syringes were not exposed to direct light thanks to their sterile bag packaging. It implies that morphine was protected from that degradation pathway. Then, special attention was done to not introduce air in syringes during manipulations in order to protect baclofen from a potential oxidation by dissolved oxygen. No change in UV spectra was highlighted for morphine and baclofen during the study. They have been remaining identical to those of a fresh morphine and baclofen solution.
pH determinations
About the pH, no change was observed whatever the study conditions. The difference between mixture 1 and 2 is explained by the difference of morphine concentration. With 10 mg/mL of morphine, mixture 2 is more acid than mixture 1 which as only 1 mg/mL of morphine.
Physical stability
No modification of samples visual aspect was observed during the stability study as well as no significant change of turbidity. Samples optic density at 350 and 700 nm remained very low from day 0 until the end of the study. These results are in favor of an absence of particles aggregation.
Conclusion
A UPLC UV stability indicating method was developed and validated according to the ICH guidelines to study the stability of morphine and baclofen, in polypropylene syringes. Two different mixtures were studied to assess their physical-chemical stability. During the assays, chromatograms were strictly similar and without appearance of degradation products. After seven days, our study showed that every 95 % confidence intervals calculated had their lower bounds greater than 95 %. Moreover, no change appeared about the pH, turbidity or color of samples. All these results are in favor with a physically and chemically stable preparation between the two concentrations studied, in polypropylene syringes at both 5°C ± 3°C and 25°C ± 2°C. This stability period ensure the feasibility of a transport for this kind of preparations. In addition, in view of these results, advance syringes preparation for patients could also be feasible. In order to go further, intermediate mixtures could be studied (morphine 10 mg/mL -baclofen 0.08 mg/mL or morphine 1 mg/mL -baclofen 1.6 mg/mL).
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